The Hidden
Hospital Cost

Most coverage of hospital pricing in India lands on a familiar charge: hospitals overcharge. That's true, but it understates what's actually happening, and it points reform in the wrong direction. The sharper problem is structural. A corporate hospital sits on both sides of the same transaction — it negotiates bulk medicine and device purchases the way a large institutional buyer would, then dispenses those same products to an admitted patient who has no second supplier to compare against. The retail chemist down the road operates under competitive pressure on both ends. The hospital pharmacy, for the duration of an admission, does not. That asymmetry — not a violation of any printed price ceiling — is where the money is made.

Put plainly: hospitals negotiate like institutional buyers and dispense within a captive retail environment. Nothing about that arrangement is illegal. The Drug Price Control Order (DPCO) sets ceilings on what manufacturers can charge for a defined list of scheduled formulations, and the National Pharmaceutical Pricing Authority (NPPA) monitors compliance at that level. Neither has ever attempted to govern what a hospital bills a patient with no real alternative once admitted. The result is a market-structure failure dressed up as a pricing story — and it is compounded by a severe shortage of doctors, a paramedical system that pushes routine tasks onto scarce specialists, and an insurance system that, once a patient stops paying directly, removes much of the remaining price discipline.

The DPCO Myth and What Regulation Actually Covers

There is a widespread belief — even among policy-aware citizens — that the Drug Price Control Order protects patients from hospital overcharging. It does not, at least not at the point of dispensing. The DPCO sets a ceiling on what a manufacturer can charge at the ex-factory level for scheduled formulations, and the NPPA monitors that the MRP printed on the pack stays within that ceiling. Neither body has ever extended its mandate to what a hospital bills a patient for medicines dispensed from its in-house pharmacy during an admission.

The Competition Commission of India's 2021 market study on the pharmaceutical sector put a number on the resulting gap. Across the formulations the Commission analysed, the median retail margin came out to roughly 28% of the final price — well above the 16% statutory cap that applies to scheduled drugs, and even above the 20% norm manufacturers commonly set for non-scheduled ones. The Commission's own conclusion was direct: when purchase of prescribed drugs from the hospital pharmacy is effectively mandatory for in-patients, that pharmacy is insulated from retail competition altogether. A 2016–17 Maharashtra FDA study illustrates the same dynamic for uncapped consumables: it found hospitals selling balloon catheters at over four times landed price and guiding catheters at over five times — margins of 472% and 529% respectively, with the same regulatory submission separately documenting 300% margins on oxygen bags and 500% on urinary bags. Cardiac stents showed an even starker version of the same pattern before they were brought under price control: data published by NPPA itself, and cited publicly by the Minister of Chemicals and Fertilizers at the time the price cap was announced, showed hospital trade margins on stents running as high as 654% — which is precisely why the regulator capped stent prices outright in February 2017. That history is itself instructive — it shows the spread can be closed once a category is brought under direct price regulation, but catheters and most other consumables and devices remain outside that net today.

For non-DPCO drugs — branded specialty medicines, patented molecules, and the growing category of high-cost specialty injectables and consumables — the gap is wider still, because manufacturers set MRP freely. This is also where the institutional-buyer dynamic is clearest: large hospital chains, like large public procurement agencies, can negotiate purchase prices far below MRP simply by virtue of buying in volume. The evidence that pooled, institutional buying power genuinely works is not theoretical — it is now a well-established, multi-state pattern in Indian public health procurement. A 2005 peer-reviewed study found Delhi's pooled-procurement programme saved the government roughly 30% of its annual drugs bill. Tamil Nadu's Medical Services Corporation (TNMSC), which has run a similar model since 1994 and now procures roughly 95% of essential drugs and supplies for over 3,000 government facilities statewide, has been credited with comparable savings of around 30% and has become the template other states are actively copying: Kerala, Rajasthan, Odisha, Bihar, and Uttar Pradesh have all stood up their own versions, and Uttar Pradesh's adaptation alone lifted essential-medicine availability across its warehouses from 34% to 88% between December 2020 and July 2024. Disease-specific pooled procurement can go further still — a National Cancer Grid pilot covering 40 oncology drugs across 23 cancer centres achieved savings ranging from 23% to 99%, with a median of 82%, against maximum retail prices. None of these are private-hospital examples, and pooled-procurement bodies are not immune to their own failures — Kerala's KMSCL, for instance, was reported in early 2025 to owe pharmaceutical suppliers nearly ₹694 crore in pending payments, a reminder that controlling price is not the same as sustaining the system that delivers it. But together they demonstrate that the institutional-buying advantage this report describes inside private hospitals is the same lever India's own public health system has used, repeatedly and at scale, to cut costs by roughly a third. Individual private hospitals wield a version of that same leverage, but neither the Ministry of Health, IRDAI, nor NPPA currently has a clear mandate over what happens to that saved margin once the product crosses from procurement into a patient's bill.

The retail-level version of the same logic is Jan Aushadhi, the government's network of generic-medicine stores, which has grown from 80 outlets in 2014 to roughly 18,000 today, serves an estimated 15 lakh customers daily, and sells medicines at 50–80% below comparable branded prices — delivering, by the government's own March 2026 accounting, more than ₹40,000 crore in cumulative citizen savings. One independent analysis put the multiplier simply: every rupee spent at a Jan Aushadhi store saves the household roughly six rupees relative to the branded equivalent. None of these models address the specific captive-pharmacy dynamic inside a private hospital admission — but they are clear, current proof that disclosed, competitively-procured pricing is achievable in India at national scale, not a theoretical import from elsewhere.

Captive Demand, Captive Retail: The Mechanism Behind the Bill

Most industries keep buying and selling functions separate, and that separation is what disciplines prices — a retailer who pays too much for inventory loses to a competitor who negotiated better, and a retailer who charges too much loses customers to a rival down the street. A hospital pharmacy occupies both roles at once. It buys with the purchasing leverage of an institutional buyer, like a large-volume tender bidder. It dispenses to a patient who, for the duration of an admission, has nowhere else to go — a captive retail environment rather than a competitive one. That combination, not any single act of overcharging, is the structural feature worth naming.

Part of what makes the procurement advantage as large as it is comes from a mechanism the article's headline framing doesn't fully surface: distribution channel elimination. Large hospital chains, particularly multi-city corporate groups with centralised procurement teams, frequently bypass one or more layers of the conventional supply chain — negotiating directly with manufacturers or their clearing-and-forwarding agents rather than purchasing through the distributor and stockist layer that retail pharmacies depend on. The effect is that hospitals secure prices that reflect the absence of intermediary margins — savings that accumulate at the point of procurement but are not required to be disclosed or transmitted forward to the patient. Institutional supplies already account for roughly 31% of the Indian pharmaceutical distribution market by value, served through procurement channels structurally distinct from retail, per industry data for 2024. A live CDSCO consultation, reported in June 2026, proposes to extend the same logic to medical devices — allowing hospitals to import devices directly from global manufacturers, further compressing the intermediary layer. The proposal is explicitly framed as a cost-reduction mechanism; whether any resulting savings would reach patients is, once again, not addressed.

Seen this way, the hospital pharmacy is not really functioning as a pharmacy in the conventional sense. Economically, it behaves as a captive distribution channel and a margin-generating unit within the broader hospital business. A 2017 EPW analysis reported that pharmacy departments contributed more than 30% of revenue in some hospital settings it examined, with margins on drugs and devices reaching 25–30% — a single-source finding rather than an industry-wide audited figure, but directionally consistent with the broader pattern this report describes. Framed against the doctor-acquisition costs, ICU infrastructure, and insurer-negotiation losses that hospitals also carry, it's reasonable to read pharmacy margin as one of the ways hospital operations are being financed — though the precise allocation of that margin across a hospital's cost centres isn't independently documented and should be read as informed interpretation, not an audited fact.

The Same Molecule, Wildly Different Prices — Even Outside the Hospital

The discount-transmission failure described in this report is sharpest inside a hospital admission, where the patient is genuinely captive. But a milder version of the same disclosure gap exists in the open retail market too — among competing brands of the identical molecule, where a patient is, in theory, free to choose. RxIntel's own PriceIQ tracker, which monitors 541 branded formulations across 10 molecules, currently flags significant price variation in 7 of them. The spread is not a rounding error; it runs into multiples that would be considered extraordinary in almost any other consumer category.

This is not a hospital-specific phenomenon, and it is not illegal — manufacturers are free to set MRP on non-scheduled formulations, and a 31x or 49x spread between the cheapest and costliest brand of the same active ingredient is, in itself, simply a function of free pricing on branded generics. What it demonstrates is the same underlying problem this report describes inside hospitals, visible at a different point in the chain: the patient, whether admitted or standing at a retail counter, generally has no easy way to see that the molecule they need is available 10, 30, or 50 times cheaper under a different brand. The pattern is not confined to the molecules PriceIQ currently flags, and it is not new — it has been independently documented, repeatedly, in peer-reviewed pharmacology literature. A study published in Cureus and indexed in PubMed Central examined exactly the drug class apixaban and ticagrelor belong to — anticoagulants, antiplatelets, and fibrinolytics used for thromboembolic disorders — and found cost variation as high as 2,455.55% for prasugrel 5mg and 1,408.44% for prasugrel 10mg across competing Indian brands, benchmarked directly against both the DPCO ceiling price and the Jan Aushadhi generic price. A separate peer-reviewed study of 696 branded eye and ENT formulations found price variation against Jan Aushadhi's generic equivalents reaching 419% for latanoprost and 294% for xylometazoline, and — counterintuitively — found that a larger number of competing brands for the same molecule is associated with greater price dispersion, not less, suggesting that brand proliferation in India does not function as the price-disciplining competition it would in most other markets. The same body of research noted that unbranded generics — the Jan Aushadhi-type products sold without a proprietary name — account for only a small fraction of India's domestic pharmaceutical market, contrasting India's uptake with several neighbouring countries where unbranded generic dispensing is substantially higher. This is an observation about domestic dispensing patterns, not India's overall pharmaceutical capacity: India manufactures approximately 20% of the world's generic medicines by volume and is one of the largest global suppliers, but domestically, branded versions of those same molecules dominate dispensing and the unbranded alternative remains marginal in most private-sector settings.

Terminology note: References to "generic market share" in comparative research may refer specifically to unbranded generics rather than branded generics. India remains one of the world's largest generic medicine producers by volume, while branded generics — the same molecules sold under proprietary names by manufacturers — continue to dominate domestic dispensing.

Consumables and Diagnostics: An Unregulated Layer

Drug pricing at least has an MRP printed somewhere, even if hospitals face no obligation to discount it. Consumables — surgical gloves, IV lines, catheters, sutures, disposable drapes, syringes, oxygen and urinary bags, intraocular lenses — largely don't. The hospital buys them on its own procurement terms and bills them at whatever price it sets, with little independent benchmark available to the patient for comparison.

The table below uses only figures that trace to the same Maharashtra FDA regulatory submission cited earlier in this report — a study conducted from December 2016 to April 2017, reviewed and reported on by Business Standard, and formally submitted to NPPA for action. These are not estimates or anecdote; they are the margins a state drug regulator documented and put on the official record.

Source: Maharashtra FDA study (Dec 2016–Apr 2017), reported in Business Standard (July 2017) and submitted to NPPA for action; NPPA's own published cardiac stent margin data (2017). Devices and consumables in this table, other than stents, remain outside any price-control net today.

The pricing story does not end with medicines and consumables. Behind many of the cost pressures facing hospitals sits another structural constraint: a shortage of doctors and specialist clinical capacity. Understanding hospital economics requires examining both sides of the equation — revenue generation and workforce scarcity.

The Doctor Crisis That Powers the Price Crisis

Every discussion of hospital overcharging eventually arrives at a simpler, structural truth: India does not have enough doctors. The government's own figures, compiled from National Medical Commission registration data and presented in Parliament as of July 2024, put the ratio at roughly one allopathic doctor for every 834–836 citizens. That is a real improvement over the figure widely cited a decade ago, and it is worth correcting a persistent misconception alongside it: India is frequently compared against a "WHO benchmark of 1 doctor per 1,000 people," but the WHO does not in fact issue that specific national ratio as a formal recommendation — its actual workforce-density target is a composite measure of 4.45 doctors, nurses, and midwives combined per 1,000 population. The real, narrower problem is distributional rather than purely numerical: specialist shortages remain severe, and in many Tier 2 and Tier 3 cities a single specialist may be the only practitioner of their kind in the area.

This scarcity plausibly has consequences for hospital costs, though the mechanism is best read as informed interpretation rather than an established fact. Because qualified specialists are expensive to retain full-time, many mid-tier private hospitals reportedly rely on a "visiting consultant" model — a specialist attached to multiple hospitals, rotating rounds and billing each institution separately. One reasonable reading of this arrangement is that specialist scarcity ends up being monetised twice over: once through the doctor's own consultation fee, and again through the premium a hospital can charge for the association. This is an analytical interpretation, not a documented practice at any named institution, and the available evidence on any resulting effect on consultation depth or care quality remains anecdotal rather than peer-reviewed.

Insurance: Removing the Last Check on Price

Out-of-pocket spending accounted for 43.4% of India's total health expenditure in 2022-23 — the most recent year for which official National Health Accounts data is available — up from 39.4% the year before, reversing nearly a decade of steady decline. A separate, peer-reviewed analysis of hospitalised care found that medicines specifically make up roughly 29% of out-of-pocket spending for inpatients and over 60% for outpatients, which is part of why direct cash-paying patients remain price-sensitive even inside a hospital. But for the growing share of admissions covered by insurance, the dynamic changes. An insured patient experiences the bill differently: they sign a cashless authorisation at admission and often do not scrutinise a fully itemised bill the way a cash-paying patient would. That shift in who feels the price creates incentives for higher utilisation and more aggressive billing, even without alleging any specific scheme at any specific hospital.

The numbers behind this shift are no longer theoretical. IRDAI's own 2024-25 Annual Report recorded 3.26 crore health insurance claims settled that year, with insurers paying out ₹94,248 crore — and Aon's 2026 Global Medical Trend Rates Report projects India's employee medical plan costs will rise a further 11.5% in 2026, moderating slightly from 13% in 2025 but still running at roughly 2.5 times India's general consumer inflation rate. A separate, peer-reviewed study of COVID-19 hospitalisations in Kerala offers a related data point worth noting, even though it measures public-versus-private cost burden rather than insured-versus-uninsured billing specifically: 37.6% of households treated in public-sector hospitals incurred catastrophic health expenditure, compared with 64.3% of those treated in private-sector hospitals — broadly consistent with the captive-pricing dynamic this report describes, though not a direct measurement of it.

The structural concern, raised by health economists and consumer advocates rather than asserted here as documented fact, is a feedback loop: as insured billing grows less price-sensitive, insurers' claim payouts rise, premiums are repriced upward to cover the higher loss ratio, and the next year's patients — including those who never made a claim — pay more to renew. None of this requires any hospital to do anything illegal. It only requires the immediate purchaser of medical services (the patient) to be insulated from the price signal that would otherwise discipline it. Insurers are not passive in this dynamic, however: they can and do exert downward pressure of their own through package-rate negotiations and network-hospital contracting, mechanisms that have a real moderating effect on billing even though the terms of those negotiations are rarely visible to the patient they ultimately protect.

Who Could Strengthen This — And What Stands in the Way

The accountability gap in Indian hospital pricing is not the product of any single actor's failure. It reflects a regulatory architecture built for an earlier, smaller, and less corporatised hospital sector — one that has not been comprehensively redesigned to keep pace with the growth of large hospital chains.

NPPA and DPCO govern what the manufacturer prints on the box; they have no mandate over what the hospital charges the patient for the contents. IRDAI regulates insurers, not the hospitals insurers pay. State Clinical Establishments Acts license hospitals but generally do not set tariffs — and the adoption gap is specific and sizeable: only around a dozen states and most Union Territories have adopted the central Act, while two of India's largest healthcare markets, Maharashtra and the NCT of Delhi, currently sit outside it entirely. The National Medical Commission governs doctors' professional conduct but not hospital billing practices. The table below makes the pattern explicit: each regulator's mandate stops just short of the hospital-to-patient transaction, and no single body currently owns the gap between them.

The Gap Is Already on the Record

This is not a gap this report is the first to notice. It has already reached the Supreme Court, Parliament, and India's audit and transparency institutions — and each has pointed at the same hole. It is worth noting that public attention on this specific issue has reached Parliament before: in 2012, Aamir Khan's documentary talk show Satyamev Jayate aired an episode on medical malpractice and overcharging that resonated widely enough to prompt an invitation for Khan to testify before the Rajya Sabha's Standing Committee on Commerce, where he advocated for generic medicines and greater pricing transparency. That episode aired fourteen years before this report. The structural problem it raised has since been confirmed by the Competition Commission, documented by state drug regulators, reviewed by the Supreme Court, and examined by a Parliamentary standing committee — yet the procurement-to-patient disclosure gap it pointed at remains, in 2026, largely intact.

In Siddharth Dalmia & Anr. v. Union of India (Writ Petition (C) No. 337 of 2018), decided on March 4, 2025, a bench of Justices Surya Kant and N. Kotiswar Singh — Justice Surya Kant has since become the 53rd Chief Justice of India — heard a public interest litigation arguing that private hospitals compelling patients to purchase medicines, implants, and devices exclusively from in-house pharmacies, often at rates far above the open market, infringes the right to health under Article 21 of the Constitution. The Court agreed the practice raised genuine concern, but declined to issue a mandatory nationwide directive, holding that public health and hospitals fall under the State List of the Constitution and are accordingly best addressed through state-level policy. It disposed of the petition by directing all state governments to "consider this issue and take appropriate policy decision as they deem fit." As of this report, more than a year on, no comprehensive state policy directly responding to that order has been documented — the order remains, in practice, an unresolved directive rather than a closed matter.

Separately, Parliament's own Standing Committee on Chemicals and Fertilisers, chaired by Mr. Azad Kirti Jha, tabled a report on December 1, 2025 titled "Price Rise of Medicines in the Pharmaceutical Sector Impacting the Lives of Ordinary Citizens Adversely — A Review." Contemporaneous coverage of the report cited markups of several hundred percent on some commonly prescribed branded generics, driven not by innovation cost but by unrationalised trade margins. What the Committee itself documented directly — and what matters most for this report's argument — was a finding that lands almost exactly on its central thesis: price-to-stockist (PTS) data, the figure that would reveal the real spread between what is paid upstream and what is billed to the patient, remains undisclosed to the public. The Committee recommended amending the DPCO 2013 to permit trade-margin rationalisation on a permanent basis; current law only permits it as a time-limited measure, which is why the 2019 oncology-drug margin cap was structured as a "pilot" rather than a standing rule. A related report from the same Committee separately recommended bifurcating medical devices from pharmaceuticals under DPCO and commended the government-run AMRIT Pharmacy initiative — which sells medicines and devices at roughly 15% below average market prices on a margin of just 5%, and currently operates 207 stores inside public-sector hospitals — as a working model worth expanding.

Government audit institutions have separately flagged adjacent billing-integrity issues: the Comptroller and Auditor General's Report No. 17 of 2022, a performance audit of drug procurement and supply under CGHS, documented overcharging patterns including inadmissible charges and costs improperly folded into package rates — a narrower government scheme than the private-hospital focus of this report, but evidence from India's apex audit body that billing-integrity gaps of this kind are real and already being formally tracked.

Transparency law has also begun to engage with this gap directly. In a case arising from a patient's family being unable to obtain satisfactory billing information from a private hospital, an information commission observed that private entities providing essential public services — hospitals among them — ought to be brought within the ambit of the Right to Information Act through a state-specific amendment to the law. That recommendation has not been enacted, and RTI today does not reach private hospital billing as a matter of course. But it is a third, independent signal — alongside the Supreme Court's order and Parliament's own committee findings — that the absence of a mechanism to compel disclosure of hospital pricing is increasingly being treated as a gap worth closing, not a settled feature of the system.

Hospital chains, like any large and economically significant industry, also have the resources to engage actively in policy consultations on proposed price or margin regulation — a pattern visible in the documented industry pushback against earlier price-control measures, including trade-margin rationalisation efforts. This is a live contest, not a settled one: as of early 2026, the Association of Healthcare Providers India has a pending Supreme Court petition seeking to exempt medical professionals from the Consumer Protection Act entirely, relying on a 2024 precedent that exempted lawyers from the same law, and asking the Court to revisit the 1995 ruling that currently allows patients to pursue hospitals as "service providers" under consumer law. None of this is evidence of impropriety by any party — it is simply how regulation gets negotiated in any sector — but it does mean reform in this space is actively contested from multiple directions, not just slow.

The Wider Ecosystem: From a Hospital Story to a Financing Story

Treated narrowly, this looks like a story about hospital pricing. Treated at the right scale, it is a story about how healthcare affordability in India is determined — and the actors involved extend well beyond the hospital gate: manufacturers who set MRP, distributors and stockists who take a margin, hospitals that combine institutional buying with captive retail, doctors whose prescribing patterns shape demand, insurers who underwrite the bill, regulators whose mandates each cover one slice of the chain, and patients who ultimately fund all of it. A reform that targets only one node — say, capping hospital margins without addressing branded-generic pricing or insurer claim review — risks seeing the saved cost reappear somewhere else in the chain. This is, in effect, a quieter but no less consequential driver of medical inflation in India than the headline price of any single drug.

Two second-order effects deserve more attention than they typically get. First, when pharmacy margin is a meaningful revenue line for a hospital, it can create a quiet disincentive to steer patients toward lower-priced generic alternatives, since margin-rich branded options are more lucrative to dispense — a dynamic that echoes CCI's broader finding that branded generics retain market share in India despite the availability of cheaper, bioequivalent unbranded alternatives. Second, because insurance distances the patient from the price signal, hospital margins captured today plausibly feed into the premium base insurers price in for everyone tomorrow — an effect that is logically coherent but, like several points in this piece, not independently quantified in available public data and should be read as informed inference rather than measured fact. Greater patient billing transparency — visibility into hospital procurement costs alongside what's billed — is the common thread that would make both effects easier to monitor and address.

What Meaningful Reform Looks Like

The Closing Account

The same medicine, in the same box, can carry the same printed MRP whether you buy it at your local chemist or receive it through a drip in a private hospital. But one of those transactions occurs in a market with some degree of competition and price transparency. The other occurs when you are admitted, dependent on the institution treating you, and structurally unable to compare prices or walk away.

The retail chemist who discounts that box is operating under competitive pressure that keeps some of the manufacturer's margin flowing back to the customer. The hospital that buys the same product at a steep institutional discount and bills it at full MRP is not breaking any law in doing so — it is simply operating in a space where no law currently requires it to share that saving.

Behind the pricing story sits a related, harder-to-fix one: a doctor shortage that is plausibly compounding the cost problem, an insurance system that is removing some of the remaining price discipline at the point of care, and a regulatory map where every agency's mandate stops just short of the transaction that matters most to the patient.

A note on limitations: Hospital-level procurement pricing is not publicly disclosed in a standardised manner in India, which means many of the market-wide patterns discussed here — including the scale of the procurement-to-patient spread across the sector — cannot yet be quantified systematically. The documented examples in this piece illustrate the mechanism; they are not a verified national average.

RxIntel Research Team — Pharma intelligence · June 2026
Published: June 2026  ·  Last reviewed: June 2026

← Back to INSIGHTS  |  priceiq.rxintel.link